Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions

CME Congresses .

Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions

Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL

CME Congresses .

Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL

Aug 21st 2023- Dr. Ashwin Kishtagari- His Take on the Recent Approval of Quizartinib by FDA in AML

CME Congresses .

Aug 21st 2023- Dr. Ashwin Kishtagari- His Take on the Recent Approval of Quizartinib by FDA in AML

Aug 16th 2023- Dr. Jayastu Senapati- Prognostic Impact of Splicing Factor Mutations in Patients with Newly Diagnosed AML

CME Congresses .

Aug 16th 2023- Dr. Jayastu Senapati- Prognostic Impact of Splicing Factor Mutations in Patients with Newly Diagnosed AML

Aug 8th 2023- Dr. Tania Jain- Haploidentical Donor Hematopoietic Cell Transplantation for MDS/MPN Overlap Neoplasms: Results from a North American Collaboration

CME Congresses .

Aug 8th 2023- Dr. Tania Jain- Haploidentical Donor Hematopoietic Cell Transplantation for MDS/MPN Overlap Neoplasms: Results from a North American Collaboration

Aug 1st 2023- Dr. Samer Al Hadidi- Risk of Infections Associated with the use of Bispecific Antibodies in Multiple Myeloma

CME Congresses .

Aug 1st 2023- Dr. Samer Al Hadidi- Risk of Infections Associated with the use of Bispecific Antibodies in Multiple Myeloma

July 25th 2023- Dr. Olalekan Oluwole- His Take on the Overall Survival Update from the Randomized ZUMA-7 Trial

CME Congresses .

July 25th 2023- Dr. Olalekan Oluwole- His Take on the Overall Survival Update from the Randomized ZUMA-7 Trial

July 17th 2023- Dr. Jordan Gauthier- CD19 CAR T-Cell Therapy & Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results

CME Congresses .

July 17th 2023- Dr. Jordan Gauthier- CD19 CAR T-Cell Therapy & Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results

July 7th 2023- Bu-Flu Versus Bu-Cy for AML Patients Undergoing Haplo: a Multi Center Randomized Phase III Trial by Ling Yiwen and Colleagues

CME Congresses .

July 7th 2023- Bu-Flu Versus Bu-Cy for AML Patients Undergoing Haplo: a Multi Center Randomized Phase III Trial by Ling Yiwen and Colleagues

May 9th 2023- Dr. Olalekan Oluwole – Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL

CME Congresses .

May 9th 2023- Dr. Olalekan Oluwole – Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL